LEO Pharma announced that the FDA has approved Taclonex Topical Suspension (calcipotriene and betamethasone dipropionate), 0.005%/0.064% for the treatment of body plaque psoriasis for up to 8 weeks in patients ≥18 years.
A handheld nonablative fractional laser is safe and seems effective for home use for treating periorbital wrinkles.
Treatment of chronic immune-mediated diseases with tumor necrosis factor (TNF) inhibitors does not result in any short-term increase in cancer incidence, compared with other commonly used therapies for these conditions.
Nuvo Research and Galderma Laboratories announced that the FDA has approved a supplemental New Drug Application (sNDA) for Pliaglis (lidocaine/tetracaine) 7%/7% Cream for use on intact skin in adults to provide topical local analgesia for superficial dermatological procedures (eg, dermal filler injection, pulsed dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal).
Quadex Labs announced the release of Viroxyn Professional Use (benzocaine 7.5%, benzalkonium chloride 0.13%), a single application cold sore product available exclusively through healthcare professionals.
Patients with localized scleroderma (morphea) often experience delay in diagnosis and variability in treatment that is based more on the specialty of the provider than disease characteristics.
Both atopic dermatitis (AD) and loss-of-function mutations in the filaggrin gene (FLG) are independently associated with an increased risk of developing chronic irritant contact dermatitis (ICD), with people having both mutations at about a five-fold higher risk.
Patients with rapidly progressive alopecia areata (RPAA) tend to show favorable prognosis regardless of treatment selected.
Stiefel, a GlaxoSmithKline company, announced that the FDA has approved a supplemental New Drug Application (sNDA) for Sorilux (calcipotriene) foam, 0.005%. The expanded indication now includes the topical treatment of plaque psoriasis of the scalp in patients aged >18 years.
Compared with other anti-psoriatic therapies, systemic anti-inflammatory treatment of patients with severe psoriasis with biologic agents or methotrexate is associated with a lower combined risk of death, myocardial infarction, and stroke.
